Vestor Capital LLC Acquires 71,688 Shares of Royalty Pharma PLC $RPRX

Posted by Brian Himes on Jul 31st, 2026

Vestor Capital LLC grew its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 597.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 83,688 shares of the biopharmaceutical company’s stock after purchasing an additional 71,688 shares during the quarter. Vestor Capital LLC’s holdings in Royalty Pharma were worth $4,014,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the business. Phillips Wealth Planners LLC boosted its holdings in shares of Royalty Pharma by 1.9% in the 4th quarter. Phillips Wealth Planners LLC now owns 13,113 shares of the biopharmaceutical company’s stock worth $521,000 after buying an additional 242 shares during the last quarter. Strs Ohio increased its holdings in Royalty Pharma by 2.8% during the fourth quarter. Strs Ohio now owns 9,318 shares of the biopharmaceutical company’s stock worth $360,000 after buying an additional 252 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in Royalty Pharma by 0.6% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 43,287 shares of the biopharmaceutical company’s stock worth $1,673,000 after buying an additional 255 shares during the last quarter. Cary Street Partners Financial LLC raised its position in Royalty Pharma by 1.1% in the fourth quarter. Cary Street Partners Financial LLC now owns 24,405 shares of the biopharmaceutical company’s stock worth $943,000 after acquiring an additional 260 shares during the period. Finally, Bessemer Group Inc. raised its position in Royalty Pharma by 34.7% in the first quarter. Bessemer Group Inc. now owns 1,094 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 282 shares during the period. 54.35% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Christopher Hite sold 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $56.52, for a total value of $5,652,000.00. Following the sale, the executive vice president directly owned 459,399 shares of the company’s stock, valued at $25,965,231.48. This trade represents a 17.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gregory Norden sold 3,045 shares of Royalty Pharma stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $53.00, for a total transaction of $161,385.00. Following the sale, the director owned 191,803 shares of the company’s stock, valued at approximately $10,165,559. The trade was a 1.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 393,009 shares of company stock worth $21,601,827. Insiders own 18.84% of the company’s stock.

Royalty Pharma Stock Down 0.3%

RPRX opened at $59.02 on Friday. The firm has a market capitalization of $33.99 billion, a P/E ratio of 40.15, a price-to-earnings-growth ratio of 10.48 and a beta of 0.43. Royalty Pharma PLC has a one year low of $34.08 and a one year high of $60.44. The company has a fifty day moving average price of $56.11 and a 200-day moving average price of $49.80. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.66 and a quick ratio of 2.66.

Royalty Pharma (NASDAQ:RPRX – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. The company had revenue of $630.58 million for the quarter, compared to the consensus estimate of $881.69 million. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%. Equities research analysts expect that Royalty Pharma PLC will post 5.18 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a $0.235 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.94 annualized dividend and a dividend yield of 1.6%. Royalty Pharma’s dividend payout ratio (DPR) is presently 63.95%.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. boosted their target price on shares of Royalty Pharma from $50.00 to $58.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Weiss Ratings cut shares of Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 15th. TD Cowen lifted their price target on shares of Royalty Pharma from $50.00 to $65.00 and gave the stock a “buy” rating in a report on Monday, July 13th. UBS Group upped their price objective on Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, April 21st. Finally, Wall Street Zen raised Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Seven research analysts have rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $56.57.

Get Our Latest Stock Analysis on RPRX

Royalty Pharma Company Profile

(Free Report)

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.